Premium
Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers
Author(s) -
Rasmussen Birgitte Buur,
Larsen Lotte Seiding,
Senderovitz Thomas
Publication year - 2005
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.2005.00735.x
Subject(s) - labetalol , medicine , pharmacokinetics , crossover study , bioavailability , population , betamethasone , anesthesia , area under the curve , pharmacology , placebo , alternative medicine , environmental health , pathology , blood pressure
Objectives In two separate trials, we studied the concomitant administration of atosiban with labetalol and betamethasone to determine any possibility of a clinically relevant pharmacokinetic interaction. Design Study 1 was an open‐label, single dose atosiban, multiple dose labetalol, interaction study. Study 2 was an open‐label, randomised, three‐period crossover pharmacokinetic study. Setting The studies were carried out at the Clinical Pharmacology Unit of AAI Deutschland GmbH & Co KG, Neu‐Ulm, Germany. Population The study population consisted of healthy female volunteers. Methods In Study 1, 14 healthy female volunteers participated. On study day 1, a 12‐hour intravenous infusion of 114.75 mg atosiban was administered; on days 2–4, participants received labetalol orally (100 mg twice daily), and on study day 5 they received the combined treatment. In Study 2, a total of 18 healthy female volunteers received, on three separate occasions, a 12‐hour intravenous infusion of 114.75 mg atosiban, a single intramuscular injection of 12 mg betamethasone or the two drugs in combination. Main outcome measure For Study 1, the outcome parameter for atosiban was area under the plasma concentration–time curve (AUC); the study parameters for labetalol were AUC, maximum plasma concentration ( C max ) and time to C max ( t max ). In Study 2, AUC, C max and time to C max ( t max ) were assessed for atosiban and betamethasone. Results Labetalol had no clinically relevant influence on the bioavailability (AUC) of atosiban. For labetalol, the co‐administration with atosiban did not affect the extent of bioavailability, however, C max decreased by 36% and t max increased by 45 minutes. The C min was not affected by atosiban. The betamethasone and atosiban combination led to similar mean plasma concentration–time curves as the administration of each substance alone. Pharmacokinetic parameters (AUC, C max , t max ) did not differ markedly between treatments and all 90% CIs for ratios between treatments were fully within limits (80–125%). The co‐administration of atosiban with labetalol or betamethasone resulted in similar tolerability to each substance alone. Conclusion The co‐administration of atosiban with betamethasone or labetalol had no clinically relevant influence on their bioavailability or tolerability.